Charcot neuroarthropathy in the feet of patients with diabetes is not a common problem and is often under-diagnosed in clinical practice.
Treatment Options for Charcot Neuroarthropathy
Charcot neuroarthropathy in the feet of patients with diabetes is not a common problem and is often under-diagnosed in clinical practice.
Once it occurs, it can progress rapidly and result in severe foot deformity, increasing the risk of ulceration and amputation. Charcot foot is said to occur in approximately 0.2% of patients with diabetes. 1 Recognition and prompt treatment of the condition are critical to avoid complications, morbidity and potential mortality. 
Clinical Course
Charcot neuroarthropathy occurs mostly in those patients whose diabetes is complicated by severe peripheral neuropathy. The initiating factor for development of a Charcot foot is minor trauma, which often goes unnoticed by the patient due to the lack of sensation in their feet. One study suggested that 73% of patients with Charcot foot did not recall a precipitating injury or event. 1 The process can affect any of the joints within the foot or ankle, but most commonly affects those in the midfoot region. Midfoot Charcot neuroarthropathy causes a collapse of the arch of the foot, leading to a 'rocker-bottom' deformity. This subsequently causes abnormal pressure loading to the plantar surface of the foot.
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Diagnosis
Successful diagnosis relies partly on the ability of the physician to suspect and recognise the potential for Charcot neuroarthropathy. It should be considered in any patient with diabetes complicated by neuropathy presenting with a red, swollen, warm foot. The patient will have evidence of peripheral neuropathy on clinical examination, and will exhibit a difference in skin temperature between the two feet. A temperature difference of 4ºC between the feet was considered significant in one study, 6 but differences can be higher.
Plain radiographs are the first-line investigation for Charcot neuroarthropathy, and Eichenholtz described radiological stages that corresponded to his clinical classification system. 4 practice. Although we use bone scanning to aid diagnosis, we do not currently use it for monitoring disease activity as it is expensive and not readily available.
Physical Management
Offloading in the acute phase aims to eliminate the stresses to which the foot is subjected, and therefore to avoid the occurrence of microfractures and early joint deformities. 10 The gold standard device to achieve this is a total-contact cast (TCC), which is designed to be in contact with the whole plantar surface of the foot, thus eliminating areas of abnormal pressure distribution. 
Medical Therapy
Medical therapy for Charcot neuroarthropathy is aimed at the increased bone turnover experienced during the acute phase. 13 Excessive bone turnover and increased osteoclastic activity have been described in several papers.
14,15 Selby et al. showed that patients with
Charcot arthropathy have high levels of urine deoxypyridoline and bone-specific alkaline phosphatase, inferring high bone resorption and active bone formation. 16 Medical treatment was therefore postulated to be similar to other conditions with high turnover of bone, such as metastatic bone disease and Paget's disease of bone.
Use of Bisphosphonates
Bisphosphonates were first trialled in 1994 by Selby and colleagues.
They administered a course of pamidronate infusions over 10 weeks to patients with Charcot, and found improved symptoms, reduced foot temperatures and a 25% reduction in alkaline phosphatase levels. 17 This was followed by a larger, randomised, double-blind, placebo-controlled trial using 90mg pamidronate versus normal saline infusion as placebo. This was conducted by Jude et al. in four UK centres. 11 The treated group experienced a greater (but not significant) fall in temperature of the affected foot after two weeks, and improvement in reported symptoms. Measures of bone turnover were also reduced in the treatment group, suggesting a therapeutic benefit for bisphosphonates in treatment of Charcot neuroarthropathy. Further studies have supported these results.
Anderson and colleagues used pamidronate infusions and showed a statistically significant reduction in foot temperatures and reduced alkaline phosphatase levels in the treated group. 18 Pitocco et al. used oral alendronate in a randomised controlled trial. 19 They found a significant reduction in foot temperature after six months in both treatment and placebo groups, but patients treated with alendronate had a significant difference in the reduction of 1CTP levels and improvement in bone mineral density from the placebo group. Further studies comparing different bisphosphonates and different dosing regimens could be beneficial.
Use of Calcitonin
Calcitonin is similarly known to inhibit osteoclast function and reduce the number of osteoclasts in circulation. It is usually produced by the Diabetic Neuropathy
thyroid medulla. It has a safer profile for use in renal failure compared with bisphosphonates. However, its major disadvantage is that it is more difficult to administer than bisphosphonates. Bem et al. carried out a trial of intranasal calcitonin as a treatment for acute Charcot arthropathy. 20 They found that the treatment group had a greater reduction in 1CTP levels (measure of bone turnover activity) compared with control subjects, but, again, no difference in reduction of skin temperature between the two groups.
Other Medical Therapies
Further medical therapies for treatment of Charcot feet are under investigation. Current research is targeting the inflammatory pathways involved in the activation of osteoclasts and formation of a Charcot joint. 13 Various cytokines have been implicated in the inflammatory pathways and formation of osteoclasts, including tumour necrosis factor-alpha (TNF-α), interleukin-1 (IL-1), IL-6 and parathyroid hormone. These could be potential targets for future immunomodulatory therapy. In addition, the receptor activator of nuclear factor-kappa B (NF-κB) ligand (RANKL) and osteoprotegerin molecules have been discovered; they are responsible for regulating osteoclast formation, and may be a further therapeutic target. 21 Finally, low-intensity ultrasound used in conjunction with other therapies may be beneficial.
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Surgical Treatment
The Saltzman and colleagues suggested a need for surgery when they followed up 115 patients for a median 3.8 years after conservative treatment for Charcot foot. 24 They noted amputations in 2.7% and ulcer recurrence in 49.0%, some of which may have been prevented by earlier surgical intervention. The aims of surgical treatment are to produce a stable foot with minimal risk of ulceration and address the abnormal bone formed during the remodelling phase.
As Charcot neuroarthropathy patients often have significant co-morbidities and obesity, patients must have a full medical assessment including history and examination prior to any surgery.
Patients should be aware of the prolonged recovery time following these procedures, but also that, if successful, they could have improved walking ability and remain free from ulceration. The patient must again be aware that a prolonged recovery period following the procedure may be needed. Various devices can be utilised to ensure internal fixation of the joints to be fused.
Contracture of the Achilles tendon is commonly found in patients with
Charcot deformities and, if found, lengthening of the tendon should be considered at the time of surgery.
Conclusions
The 
